Prosensa Holding, a biotech engaged in the discovery and development of RNA-modulating therapeutics for the treatment of genetic disorders, filed on Friday with the SEC to raise up to $60 million in an initial public offering. The Leiden, Netherlands-based company, which was founded in 2002 and booked $11 million in licensing and collaboration revenue for the 12 months ended March 31, 2013, plans to list on the NASDAQ under the symbol RNA. Prosensa Holding initially filed confidentially on April 16, 2013. J.P. Morgan and Citi are the joint bookrunners on the deal. No pricing terms were disclosed.
